Back to Journals » OncoTargets and Therapy » Volume 10

VTD-melphalan is well tolerated and results in very high rates of stringent CR and MRD-negative status in multiple myeloma

Total article views   Abstract views HTML views PDF downloads Totals
3,606 Dovepress* 2,520 650+ 862 3,170
PubMed Central* 0 436 165 436
Totals 2,520 1,086 1,027 3,606
*Since 6 January 2017
+Since July 2016
Total mentioned Facebook Delicious Reddit Twitter Others
4 0 0 0 2 2

View citations on PubMed Central and Google Scholar